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Abstract
Neurohypophysial hormones are thought to be involved in 
alterations in fluid balance during pregnancy and delivery. 
In the course of normal pregnancy intravascular volume is 
increased whereas sodium restriction is thought to reduce 
plasma volume and cardiac output. In the present study, 
we measured the effect of long-term severe sodium 
restriction on vasopressin (AVP) and oxytocin (OT) levels 
during normal pregnancy and after delivery.
Fifty-nine healthy nulliparous women were randomized 
either for a low sodium diet (20 mmol sodium daily) or for 
a normal diet from week 12 of pregnancy onwards, 
Circulating plasma levels and urinary excretion of AVP 
and OT, their neurophysins (Np-AVP and Np-OT) and 
AVP bound to platelets were determined at regular 
intervals during pregnancy and after delivery. After com­
pletion of the study, women on a sodium-restricted diet 
were compared with control women on a normal diet 
using repeated measurement ANOVA with adjustment 
for potentially confounding variables.
After randomization, a reduction in urinary sodium 
excretion of, on average, 40-82% was found. In general, 
no effect of sodium restriction could be demonstrated on 
the various parameters (0*53< P < 0*98) with the exception
of a significantly lower 24-h urinary AVP excretion by 
non-smokers with sodium restriction compared with 
non-smokers having a normal diet (P=0‘018). For all 
parameters, clear changes were found in the course of 
pregnancy and puerperium (P<0*0001 to P<0'005). 
Platelet-bound AVP decreased and N p-O T  increased 
during pregnancy. After birth, free plasma AVP, platelet- 
bound AVP, OT, osmolality, sodium and potassium 
increased, while Np-AVP and N p-O T  decreased.
Although elevated Np-AVP and N p-O T  levels during 
pregnancy seem to indicate increased release of neuro­
hypophysial hormones, pregnancy up to 36 weeks of 
gestation is accompanied by low circulating AVP and OT 
levels.
Long-term severe sodium restriction diminishes urinary 
AVP excretion in (non-smoking) pregnant women, with­
out changing circulating levels of AVP and OT, despite 
the known reduction in circulating volume. The reduced 
circulating (plat el et-bound) AVP levels during pregnancy, 
whether or not in combination with severe sodium 
restriction, support the absence of significant non-osmotic 
stimulation of AVP during pregnancy.
journal of Endocrinology (1997) 152, 345-354
Introduction
Both the neurohypophysial hormones arginine vasopressin 
(AVP) and oxytocin (OT) are involved in volume regu­
lation in human pregnancy (Whalley & Pritchard 1963, 
Schrier 1988). In normal pregnancy, a 30-40% increase in 
plasma volume is found, possibly as a reaction to early 
vasodilation. Because of the vasodilatation, barore cep tor 
activation occurs, which might lead to non-osmotic AVP 
release (Schrier 1988). However, the exact role of AVP 
and OT in volume expansion during pregnancy remains
to be established and this work is hampered by difficulties 
in neuropeptide measurement leading to variations in 
reported plasma levels.
Sodium restriction during pregnancy is thought to 
reduce plasma volume (Brown 1988) and is considered to 
be an appropriate therapy in hypertensive pregnancy by 
some, on the assumption that hypertension is a conse­
quence of salt retention and early volume expansion 
(Hamlyn & Mordecai 1986). O n the other hand, a 
reduction of plasma volume is considered potentially 
dangerous for fetal well-being, especially in the case of
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hypertensive pregnancy complications like pre-eclampsia, 
associated with an already compromised placental circula­
tion. Nevertheless, sodium restriction is reported to 
decrease vascular reactivity in pregnancy (Jaspers et ah 
1983) and is apparently well tolerated by mother and fetus 
(Steegers et ah 1991). Conflicting views about the benefits 
of sodium restriction in pregnancy have led to the start of 
a multicentred trial in The Netherlands. It aims to evaluate 
the effects of chronic dietary sodium restriction on the 
incidence of hypertensive disorders in pregnancy and to 
examine possible maternal pathophysiological effects. 
Indeed, in women recruited earlier in the same trial, 
increased total peripheral resistance and reduced cardiac 
output were observed during long-term sodium restriction 
as compared with an unrestricted ad libitum diet (Steegers 
et al. 1991). To investigate which endocrine factors, 
besides those related to the renin-angiotensin-aldosterone 
system, are involved in these changes, AVP and O T 
maternal plasma levels were measured in pregnant women 
randomized for a low salt or a normal diet. This might not 
only confirm the involvement of both the neurohypophy­
sial hormones AVP and O T in volume regulation in 
human pregnancy, but also establish the role of AVP 
in natriuresis (Brown 1988, Prat et ah 1993) and in 
modulating vascular tone (Crooke et al. 1988) during a 
physiological challenge such as sodium restriction.
Various factors hamper reliable AVP and O T assay. The 
presence of cystyl-amino-peptidase (CAP; vasopressinase 
or oxytocinase) disturbs reliable measurement of AVP and 
O T in human pregnancy (Lauson 1974, van der Post et al. 
1994) and changes the metabolic clearance rate (MCR) of 
the peptides (Davison et al. 1989). Immediate inactivation 
of CAP during blood sampling is mandatory for a reliable 
assay. Even with optimal inactivation of CAP, free AVP 
levels in pregnancy during normal hydration are around 
the detection limit of the assay (Davison et ah 1989, 
Thornton et ah 1990, van der Post et ah 1994) and 
therefore subject to large assay variation. More information 
about O T  and AVP metabolism can be obtained by 
measuring prohormone products. The precursor molecules 
of AVP and OT, neurophysin-vasopressin (Np-AVP) and 
neurophysin-oxytocin (Np-OT), are metabolized more 
slowly (Lauson 1974). They provide, therefore, comp­
lementary information on O T  and AVP release and/or 
clearance. The same purpose is served by the measurement 
of urinary immun oreactive AVP. I mm un ore active AVP 
and O T in 24-h collections of urine are reported to reflect 
AVP and O T release over a 24-h time-span (Moses & 
Steciak 1986, Amico et al. 1987). The variation in plasma 
levels due to pulsatile, intermittent peptide release (Fuchs 
et ah 1991) is bypassed in this way. Finally, platelet- 
associated AVP is reported to change as a result of chronic 
osmotic and non-osmotic stimuli (Preibisz et ah 1983, 
Bichet et ah 1986), like reduced cardiac output, in 
non-pregnant subjects. In third trimester pregnancy, 
pi a tel et-ass ocia ted AVP levels are two to five times higher
than free circulating AVP levels (van der Post et ah 1993). 
AVP is bound to the same type of AVP receptor (van der 
Post et al 1993) present on the vascular smooth muscle 
cell. This is analogous to platelet angiotensin-II (All) 
binding (Baker et ah 1990). Platelet-associated AVP there­
fore might reflect haemodynamic alterations and altered 
vascular reactivity.
In describing AVP and OT plasma levels, excretion and 
AVP binding to platelets, this study aims to provide insight 
into AVP and OT release during physiological challenges 
such as pregnancy and low salt diets.
Subjects and M ethods
Patients
All patients participated in a multicentred study (Steegers 
et ah '1991, van Buul et ah 1995). Some data from
subgroups of the current study population have contrib­
uted to previous publications (van Buul et ah 1995). In 
the University Hospital Nijmegen, a total of 59 healthy 
nulliparous women with singleton pregnancies were en­
rolled from May 1990 onwards in a randomized study from
12 weeks gestational age onwards. All pregnancies were 
dated by the last menstrual period and ultrasound. After 
giving informed consent, women were randomly allo­
cated, by a closed envelope system, to using a low sodium 
(20 mmol/day) diet or to continue their unrestricted 
sodium intake. The 29 women allocated to the low sodium 
group started with the diet in week 14 of gestation and 
stopped immediately after delivery. All women received 
iron supplementation (65—130 mg Fe2+ daily). Com­
pliance to dietary restrictions was checked by measure­
ment of sodium excretion and sodium/creatinine ratios in 
24-h urine samples at regular intervals during pregnancy.
Study protocol
The study protocol has been described previously (Steegers
et ah 1991). Briefly, at 13, 16, 20, 24, 28, 32 and 36 weeks
of gestation and 1 and 6 weeks postpartum the following 
parameters were determined in each patient. Sodium 
excretion, sodium/creatinine ratio and urinary osmolality 
were evaluated in 24-h urine samples. Free and platelet- 
bound AVP, OT, platelet number, osmolality and sodium 
were measured in plasma.
Furthermore, in the first 21 women, Np-AVP and 
N p-O T were measured in plasma and AVP and OT in 
24-h urine samples. Blood was taken after 30 min in the 
left lateral tilt position. All blood samples were taken 
between 1400 and 1600 h. Women refrained from ciga­
rette smoking, and food and fluid intake, except for water, 
for at least 2 h before plasma sampling. Blood pressure 
measurements were taken with a DINAMAP 1846 SX 
(Kritikon, Tampa, FL, USA). Patients were labelled
journal of Endocrinology (1997) 152, 345 354
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hypertensive when a diastolic blood pressure level of at 
least 90 mmHg was found on two occasions with an 
interval of at least 4 h. Proteinuria in pregnancy was 
defined as a total protein excretion of > 0-3g /24h . 
The study protocol was approved by the Ethic Medical 
Committees of both hospitals involved.
Analytical methods
AVP and OT in plasma were measured as described earlier 
(van der Post et al. 1994). Special care was taken during 
sample preparation to inhibit CAP activity with enzyme 
inhibitors o-phenantrolin (o-PHE; Sigma Chemical Co., 
St Louis, MO, USA) and Na4-EDTA. Whole blood was 
taken from an antecubital vein into silicon-coated vacuum 
tubes (Venoject, Teruma, Leuven, Belgium) precooled on 
ice and containing 100 \x\ of a 125 mmol o-PHE/1 sol­
ution. These samples were immediately transferred to 
identical tubes containing 100 jj.1 of a 1 mol EDTA/1 
solution on melting ice. Centrifugation at 90 g  for 15 min 
at 4 °C to obtain platelet-rich plasma (PRP) and at 2000 g  
for 15 min at 4 °C to obtain platelet-poor plasma (PPP) 
resulted in less than 1% of the PRP number in the PPP.
Extraction of AVP or O T from preparations was 
performed within 1 h over octadecasilyl-silica packed 
SepPak-C18 columns (Waters Associates Inc., Milford, 
USA) using 2 ml aliquots for AVP and 1 ml aliquots for 
OT, acidified with 3 ml 0T M  HC1 to pH 1—2. Inhibitors 
were sufficiently removed by a wash with 2 ml CHC13 
and subsequently AVP and O T were eluted with 4 ml 
100% CH3OH. No CAP activity was detectable in this 
extract. Preliminary experiments showed that AVP and 
OT were stable for at least 3 weeks of storage at room 
temperature in methanol. All samples were assayed within
3 weeks of extraction. AVP and O T tracers were iodinated 
by the chloramine T method and purified by fraction­
ation on a Sephadex G-25 column. Specific activity 
was >64-8 TBq/mmol. Polyclonal anti-AVP antibody 
(Ml60480) was raised in a rabbit and used in a final 
dilution of 1:100 000. Anti-OT antibody was kindly 
donated by T Higuchi (Fukui Medical School, Matsu oka, 
Japan) and was used in a final dilution of 1:350 000. For 
OT antibody, cross-reactivity with lysine-vasopressin, 
AVP, vasotocin and desamino-D-AVP was below 0*01%. 
The detection limit, defined as B/B0 <  90%, was 0*25 pg/ 
tube for AVP and 0*125 pg/tube for OT. Intra-assay 
coefficient of variation (C.V.) was 9*7%, and the interassay 
C.V. in ten different assays was 13*4%). Recovery of 3*2 pg 
AVP/OT per ml added to whole blood of 22 pregnant 
women and nine non-pregnant controls was 57% and 59% 
and from plasma 76% and 80% respectively. In plasma 
from pregnant women, kept at 20 °C for several minutes 
without CAP inhibitors, AVP levels were equal to the 
detection limit. Platelet-bound AVP was defined as 
the difference between PRP and PPP values corrected for 
the number of platelets. The detection limit of our
platelet-associated AVP assay in this study was 0*6 pg/ml, 
which corresponds to approximately 0-24 pg/108 platelets 
(see Fig. 2),
Np-AVP and N p-O T  assays were performed at 
the Neuroendocrinology Section, C H U  Sart Tilman, 
Université de Liège, Belgium (Legros & Franchimont 
1972, Pulían et al. 1979). Briefly, plasma samples were 
obtained after centrifugation of 10 ml venous blood with 
EDTA (3 mmol/1). Small aliquots of plasma were stored at
— 20 °C until analysis. Direct assays were performed in 
100 JJ.1 plasma volumes. For Np-AVP, the detection limit 
was 0*02 ng/ml and the intra- and interassay variations 
were 6 and 10*7% respectively. N p-O T  was defined 
as total neurophysin immun ore activity minus Np-AVP 
levels. Detection limit and assay variation of total neuro­
physin immunoreactivity were 0 *2 ng/m l and 6 *1% 
respectively.
Urinary analysis for A V P  and O T
Isoelectric focusing (IEF) was performed using thin large- 
pore polyacrylamide gels. Urine samples (10 ml), acidified 
with 1 m HC1 to pH 4’0, from the pregnant women under 
study were stored at — 20 °C, extracted over SepPak-C18 
columns and dried in a vacuum rotator. The residue was 
redissolved in 25 \xl IEF medium, 10% (v/v) dimethyl- 
formamide (BDH, Poole, Dorset, UK; for gas chromatog­
raphy), 10% (v/v) glycerol (BDH) and 2*5% (v/v) 
Nonidet P-40 (Sigma), and 5 pi was taken for AVP assay. 
The same volume containing 0, 10, 20, 30, 40 and 50 pg 
synthetic AVP was used for focusing. After IEF, a sheet of 
filter paper was applied onto the gel and 5 nun gel paper 
strips of the separation tracks were cut. Each fraction was 
eluted by incubation for 1 h in 1 ml 1:8 diluted RIA  assay 
buffer and dried. Each fraction was redissolved in 125 pi 
distilled water for AVP and O T assay. W ith this pro­
cedure, median recovery of 128 pg synthetic A V P/O T 
added to 10 ml urine was 60%) and 70% respectively. All 
urine samples of one patient were focused in one run. 
Without prior separation of peptides by IEF, dilutions of 
AVP/OT extracted by SepPak columns from pregnancy 
urine did not parallel standard curves.
Urine sodium was measured by flame photometry and 
creatinine was measured spectrophotoinetrically after 
colorometric reaction with alkaline picrate. Urine protein 
was estimated using the sulphosalicylic acid test.
Plasma osmolality was established by freezing-point 
depression, plasma sodium and potassium with standard 
clinical laboratory automates.
Statistical analysis
Data were analyzed using repeated measurement 
ANOVA with missing data on the values measured at the 
second visit up to and including the seventh prenatal 
control visit. The effect of diet was adjusted for smoking,
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hypertension, age and the pretreatment value of the 
studied parameter, all regarded as potentially confounding 
variables. P values were calculated using Wald tests. The 
residuals from the resulting model were studied both on a 
between- and a within-patient level in order to identify 
outliers as well as the need for a logarithmic transform­
ation. If a logarithmic transformation was deemed useful, 
the analytic process described above was repeated after 
such a transformation. First, an analysis was made for the 
randomized group who completed the study (48 patients) 
without correction for dietary failure. Secondly, the analy­
sis was repeated after correction for dietary failure in which 
patients who failed to keep to the diet during the study 
were not included (39 patients). The magnitude of the 
changes in the mean study parameters during pregnancy 
were estimated. Differences between the diet groups 
in urinary sodium excretion or sodium/creati nine ratio 
during and after pregnancy were tested with two-way 
ANOVA. Differences between postpartum and prepartum 
values for the diet as well as for the normal group were 
tested with Student’s f-tests for paired data. Correlations 
between the studied parameters were established at the 
between- and with in-patient level.
Results
Patient characteristics and sodium excretion
O f the 59 randomized women 48 completed the study, 11 
women completely stopped the project, seven with salt 
restriction and four without. Consequently, data were 
obtained from 22 women randomized for salt restriction 
and 26 women randomized for a free diet, together 
forming the ‘intention to treat5 group. In this group, nine 
women allocated to sodium restriction continued the study 
using a normal diet early in the course of pregnancy. This 
implied that one could distinguish a * compliant to diet’ 
group consisting of 26 women without dietary restrictions 
and 13 women actually adhering to the severe sodium 
restriction. Patient characteristics are given in Table 1.
Figure 1 shows the 24-h sodium excretion and sodium/ 
creatinine ratio after randomization (‘intention to treat’, 
n=48) as well as after correction for dietary failure (‘com­
pliant to diet1, n ~ 39). The average urinary sodium excre­
tion during dietary sodium restriction (113-251 days 
gestational age) was 80-9 (s.D. 83-9) mmol/24 h and 133 
(s.D. 42*9) mmol/24 h for women without sodium restric­
tion, while the sodium/creatinine ratio averaged 7*46 
(s.D. 6'89) and 13*7 ( s .d . 4*3) respectively. This means 
that a mean reduction of 40% in sodium excretion was 
obtained by the prescription of sodium restriction. In the 
‘compliant to diet’ group, the reduction amounted to 82%, 
with an average sodium excretion of 28*8 (s.D. 33-8) 
mmol/24 h and a sodium/creatinine ratio of 2*5 (s.D. 2-4). 
The differences between the diet groups in sodium 
excretion in both analyses were highly significant during
Table 1 Characteristics of the women and the outcome of their 
pregnancies. Values are means with s.e.s in parentheses for age 
(years), gestational age (GA; days) and birthweight (g). 
Represented here are the women randomized for salt restriction 
who completed the study (n=48). Diet=those who were taking 
the salt-restricted diet; PIH = pregnancy-induced hypertension. 
There were no neonatal deaths or handicaps
Diet
(n = 22)
No diet
(n = 26) P value
Age
Smoking
PIH
GA at delivery 
Birthweight
29*6 (0-9) 28-2 (1*0) 0*90
8 10 048
2 2 0-55
275 (3) 274 (3) 0*48
3060 (94) 3077 (104) 0*77
P value for comparison of birthweight percentiles (birthweight corrected for 
gestational age and sex) between both groups was 0*98.
the period of salt restriction (P=0*0023, P<0*0001). 
However, there were no significant differences between 
both groups with respect to urinary sodium excretion 
before (93 days gestational age, P=0*29) and after (7 and
42 days postpartum, P=0*25) the dietary period.
Despite the large differences in sodium excretion, 
neither plasma osmolality (276 mosmol/kg s.D. 5 vs 276 
mosmol/kg s.D, 5) nor plasma sodium (138*6 mmol/1 s.D.
1 vs 138*6 mmol/1 s.d. 0*7) nor potassium (3*8 mmol/1 
s.d. 0*23 vs 3*8 mmol/1 s.d. 0*18) concentration differed 
significantly between the low sodium and normal diet 
groups; levels increased significantly after pregnancy: 
mean differences between pre- and postpartum values 
were osmolality, 9 mosmol/kg (P< 0*0001), sodium, 
3*2 mmol/1 (P<0*0001) and potassium, 0*27 mmol/1
(P<0*0001).
O f the 48 women followed until postpartum, four 
developed hypertension (8%).
There were no significant differences in birthweight 
between the diet groups. No perinatal deaths occurred nor 
were neonates bom with major or minor handicaps.
A V P  and O T  excretion: effects of salt restriction (see Table 2)
There appeared to be no overall differences nor time- 
specific differences between the two groups for any of the 
measured parameters, not even after correction for dietaiy 
failure. However, a statistically significant difference in 
24-h urinary AVP excretion was found during sodium 
restriction when adjusted for smoking. In non-smoking 
women, sodium restriction resulted in a significantly lower 
AVP excretion (P<0*018, see Table 2) from day 196 
onwards. Urinary OT excretion was below the detection 
limit of 1*6 pg/ml, which equals about 2*4 ng/24 h. After 
correction for dietary failure (‘compliant to diet’ analysis) 
the 13 women with salt restriction appeared to have lower 
platelet-bound AVP values at 141 days but higher levels at
Journal o f Endocrinology (1997) 152, 345-354
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Figure 1 (a and c) 24-h sodium excretion and (b and d) sodium/creatinine ratio for women randomized for severe sodium-restricted diets 
(crossed boxes) or normal diets (solid boxes), (a and b) 'Intention' means data for randomized women who completed the study (n=48,
22 salt-restricted), (c and d) 'actual diet' means data after excluding women who stopped sodium-restricted diets (n=39, 13 salt-restricted). 
Values are means with s.e.m. During sodium restriction, differences in sodium excretion were highly significant ('intention' P=00023,
'actual' P<0-0001). No significant differences existed before randomization (P=0*29) and postpartum (P=0*25). The shaded area represents 
the perinatal period.
168 days gestational age. Even so, Np-OT was lower at 
113 days but higher at 251 days gestational age.
Patients with high peptide levels at the beginning of 
pregnancy tended to have high levels later on: peptide 
levels measured before randomization significantly deter­
mined levels later in pregnancy after randomization
(P= 0-04 to P< 0-001), except for 24-h urinary AVP 
(P=026) and free AVP plasma levels (P=0-67).
Apart from the effect on urinary AVP excretion, 
smoking had no further effect on circulating peptide 
levels. Hypertension influenced the time-course of 
platelet-bound AVP values; there was a decrease only at 
113 days gestational age (P=0-003).
A V P  and O T  levels: effects of pregnancy (see Fig. 2)
Plasma levels were not corrected for recovery. Free plasma 
AVP, platelet-bound AVP, OT and their associated
neurophysins showed clear changes over time. Free AVP 
values appeared very stable during pregnancy and they 
increased after labour (P=0‘011). Platelet-bound AVP levels 
decreased during pregnancy and were found to be increased 
at the 6-weeks postpartum time-point (P<0*001). No dif­
ference was found between (42 days) postpartum values and 
values before dietary restriction was started (93 days gesta­
tional age). Np-OT increased steadily during pregnancy 
with a maximum at 7 days postpartum, and a drop at 42 days 
postpartum to 25% of the first pregnant value (P< 0-0001). 
Np-AVP decreased after pregnancy (P<0*0001). OT 
plasma levels were stable during pregnancy but showed a 
significant increase after delivery (P=0*039).
Correlations
At the be tween-patient level, free plasma AVP and 
platelet-bound levels were significantly correlated (r=0'45,
Journal o f  Endocrinology (1997) 152, 345-354
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Table 2 Changes (s.D.) in plasma levels of OT, free AVP and platelet AVP, their neurophysins, Np-OT and Np-AVP, and urinary AVP 
measured in women randomized for salt restriction ('intention to treat', n-22) compared with those without dietary restriction (n = 26) at 
various days of gestational age. Urinary AVP and neurophysin data from seven salt-restricted and fourteen women on a free diet were 
analysed
Change at:
113 141 168 196 224 251
days days days days days days P vali
AVP (ng/24 h) -  11 (23) ~ 4  (23) — 20 (23) -  7 (23) -  8 (21) 1 (22) 0-64
Platelet AVP (% change) - 2  (41) -39 (41) 56 (48) 17 (42) 14 (40) 9 (41) 0-92
Np-AVP (pg/ml) 2 (68) 7 (69) 74 (68) ~18 (68) -  10 (68) -  59 (68) 0*71
Urinary AVP (% change) -1 0  (6) — 3-8 (8) -3-6 (6) -28 (8) -21 (8) “ 17 (6) 0-018
(non-smokers)
OT (% change) 37 (22) 10 (22) -  14 (22) — 45 (23) 1 (22) 31 (22) 0-89
Np-OT (% change) 2 (15) -  13 (15) -6  (15) 2 (15) -  11 (15) 2 (16) 0-98
For urinary AVP (ng/24 h) and Np-AVP (pg/ml) absolute changes from average normal diet values are given, for all others percentage changes because of 
logarithmic transform of data. Differences are corrected for the effects of confounding factors. P values are given for the comparison by means of ANOVA of 
measured parameters from patients with and without sodium restriction (P<0-05). Comparative analysis of women who kept to their severe sodium-restricted 
diets revealed P values ranging from 0-53 to 0-94.
P=0,001). Both free circulating (r—0'46, P<0-001) and 
platelet-bound (f=0’40, P=0*004) AVP values were also 
significantly correlated with urinary osmolality.
Discussion
This is the first time that circulating AVP and O T  levels 
have been described during long-term severe sodium 
restriction in human pregnancy. The decrease in platelet- 
bound AVP levels in human pregnancy has not been 
described previously.
No overall difference or time-specific differences 
between the diet groups appeared to be present for 
both circulating peptides or prohormone products, but a 
difference was demonstrated for urinary AVP excretion. 
No significant differences in plasma sodium, potassium and 
osmolality were found between the diet groups at any of 
the time-points during pregnancy. First of all one might 
argue that these results are biased by the non-compliance 
to sodium-restricted diets of a considerable number of 
women. Although women who actually kept to their 
salt-restricted diets had indeed a huge reduction in sodium 
excretion (see Fig. 1) it was clearly difficult to keep to a 
severe sodium-restricted diet as the reduction in sodium 
excretion or sodium/creatinine ratio, on average, was less 
than 40% (see Fig. 1). From the 29 women allocated to 
sodium restriction, seven stopped the study and nine shifted 
early in pregnancy to a non-sodium-restricted diet, making 
a total of a 55% (16 out of 29) dropout. As this might lead to 
considerable selection bias, analysis was performed for the 
‘intention to treat* group (n=48) as well as for the ‘com­
pliant to diet’ group («=39). Hereby, we corrected for 
non-compliance as well as selection bias. The two analyses 
revealed no differences in the results (see Table 2).
Because we could not find any differences between the 
diet groups in circulating AVP or Np-AVP plasma levels,
journal o f Endocrinology {1997) 152, 345-354
any elevation of AVP release due to non-osmotic stimu­
lation during severe sodium restriction seems unlikely. 
Moreover, we found reduced urinary excretion of AVP 
in non-smoking women on a sodium-restricted diet. Theor­
etically, reduced circulating AVP levels might be antici­
pated during salt restriction. As reported by Davison et al 
(1981), decreased solute diuresis, as in restricted-salt diets, 
lowers distal tubular flow. Therefore, the fraction of solute 
escaping reabsorption and the residual volume to be concen­
trated are decreased, requiring decreased tubular binding of 
AVP. Since AVP is also natriuretic (Torres et al 1966), by 
regulating the amiloride-sensitive apical sodium channel in
the kidney tubules (Prat et al 1993), the mandatory dimin­
ished natriuresis during very low sodium intake can be 
achieved in part by decreased AVP binding. This fits well 
with our finding of diminished urinary AVP excretion in 
sodium-restricted non-smoking women, but not with the 
unchanged plasma levels. Perhaps, in our study, diminished 
AVP plasma levels might have escaped detection because of 
assay sensitivity (see Introduction) or because patients in our 
study were positioned in the left lateral tilt position, neces­
sary for simultaneous Doppler flow measurements of the 
fetal and uterine circulation. In this position, the maximal 
concentrating ability of the kidney is diminished probably 
because of intravascular mobilized interstitial fluids which 
will consequently suppress AVP release (Davison et al 
1981). Possible differences in neurophysin or AVP levels 
due to dietary restrictions might therefore have been 
blunted. This would, however, not influence the differences 
due to pregnancy or gestation length demonstrated in this 
study, since concentrating ability is equally suppressed post­
partum (Davison et al 1981). Nonetheless, no difference in 
plasma AVP levels in pregnant women before and after a 
7-day period of a comparable severe (20 mmol/24 h) reduc­
tion in sodium intake was found by Brown (1988), which is 
in agreement with our results.
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Figure 2 Median values of peptide levels with s.D. (dotted lines) for all women (n-48) completing the study. No correction for recovery is 
made. The shaded area represents the perinatal period, (a) AVP: stable during pregnancy with a significant increase afterwards (P=0-011). 
(fa) Platelet-bound AVP: a significant decrease during pregnancy (P<0*0001) with no significant difference between the value at 42 days 
postpartum and the first measurement in pregnancy, (c) Np-AVP (n=21): stable during pregnancy with a significant drop thereafter 
(P<0-0001) between time-points 7 (251 days of gestational age) and postpartum values, (d) 24-h urinary AVP excretion (n=21): stable 
during and after pregnancy, (e) OT: stable during pregnancy with a significant (P=0-039) increase postpartum, {f) Np-OT (n=21): a 
significant steady increase during pregnancy with a maximum at 7 days postpartum, and a drop at 42 days postpartum to 25% of the 
value at the first pregnant value (P<0-0001).
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This study was designed to overcome technical difficul­
ties in peptide measurements by simultaneous determi­
nation of peptides, neurophysins and excretion in urine 
(see Introduction). Peptide excretion in 24-h collections of 
urine are more likely a reflection of AVP release over long 
time-periods (Moses & Steciak 1986) and therefore not 
subject to short-term variation because of positi on changes. 
O f interest is that non-smoking women on a sodium- 
restricted diet were found to excrete less AVP in 24-h 
urine collections from day 196 gestational age onwards, 
compared with non-smoking women who were not 
sodium restricted (Table 2). This is in concert with studies 
by van den Horn (1981) in non-pregnant subjects, van den 
Horn (1981) found, in 13 healthy males, 52 ng AVP 
excretion/24 h in cases of 185 mmol sodium excretion/
24 h while in cases of 14 mmol sodium excretion/24 h, 
36’6 ng AVP/24 h was excreted in urine (P<0*05). This 
decrease in AVP excretion might be explained by a slight 
decrease in circulating plasma levels of AVP, not detect­
able in our study, but resulting over a 24-h period in a 
detectable decrease in urinary AVP excretion. Another 
explanation could be altered renal clearance (Robertson 
1972) through a reduction in renal plasma flow. We 
cannot differentiate between these two possibilities. 
Smoking was found to be a significant confounder in 
analyzing the urinary AVP excretion. Smoking cigarettes 
temporarily increases AVP levels in non-pregnant subjects 
(Nussey el aL 1986). It is very likely therefore that AVP 
excretion in urine is increased proportionally to the 
number of cigarettes smoked. Since data on smoking habits 
obtained by questionnaire are unreliable we did not 
analyze the urinary AVP data from women who smoked 
further. In any case, since women in our study refrained 
from smoking at least 2 h before blood sampling, smoking 
did not influence circulating peptide levels, keeping in 
mind that AVP metabolized by CAP activity in plasma is 
not detected by our AVP antibody (van der Post et a i
1994).
No lowering of AVP binding to platelets was demon­
strated by us during sodium restriction. This again indi­
cates unaltered circulating levels of AVP since free plasma 
AVP and platelet-bound AVP are positively correlated (see 
Results). On the other hand, the reduction in plasma 
volume (Brown 1988) or cardiac output during sodium 
restriction (Steegers et a l 1991) might normalize a dietary- 
induced decrease in platelet-bound AVP, since non- 
osmotic stimuli like reduced cardiac output increase 
platelet-bound AVP in non-pregnant subjects (Preibisz 
et al. 1983). It indicates that reduction in effective circu­
lating volume during sodium restriction in pregnancy 
(Steegers et a i 1991) does not lead to non-osmotic AVP 
release. Interestingly, in the course of normal pregnancy, 
we even found a gradual decrease in platelet-bound AVP 
levels (see Fig. 2), which contradicts any underfilling 
hypothesis of pregnancy (Schrier 1988). The steadily 
reduced circulating platelet-bound AVP levels found
during the course of pregnancy might indeed reflect the 
increase in blood volume during pregnancy. Decreased 
peptide platelet binding has also been described for All 
(Baker et al 1990) and parallels the decreased vascular 
reactivity to vasopressor agents found during nonnal 
pregnancy. An identical AVP (and All) receptor type 
(Via) is expressed on the vascular smooth muscle cell and 
platelet and earlier we described a (not significant) 
decrease in platelet AVP maximal binding capacity during 
third trimester pregnancy (van der Post et ai 1993), 
compared with outside pregnancy. During sodium restric­
tion in human pregnancy, an increase in vascular periph­
eral resistance is found (Steegers et al 1991). The unaltered 
AVP platelet binding found by us does not indicate a role 
for the VI a-A VP receptor type in the increased vascular 
resistance found during sodium restriction.
Basal plasma levels of free circulating AVP after correc­
tion of recovery (1 pg/ml) are in concert with the findings 
of Davison et al ('1988, 1989) and are very near to the 
detection limit of the AVP assay of 0*6 pg/ml plasma. The 
same holds for OT with its detection limit in our assay of 
0-6 pg/ml plasma (see also Fig. 2). Increased MCR of 
AVP (Davison et al 1989) probably accounts for the lower 
plasma AVP levels during pregnancy compared with after 
delivery. This is in spite of increased Np-AVP levels 
during pregnancy which indicate increased release. This is 
in agreement with activation of the neurosecretory nuclei 
in the rat brain during pregnancy (Swaab & Jongkind 
1970). From these data it might be concluded that in fact 
there is increased release of AVP leading to elevated 
Np-AVP levels but, because of the increased MCR of the 
circulating peptide, AVP levels are decreased.
The basal OT plasma levels (Fig. 2) found in this study 
are within the range of the low predelivery values found in 
most recent studies (Leake et al 1981, Fuchs et al 1991, 
Thornton et al 1992), OT plasma levels seem to rise only 
during delivery by an increase in pulse frequency and 
duration. Np-OT, measured in this study, was determined 
by subtraction assay and is considered to be an index of 
endogenous oestrogens (Legros & Grau 1973). From the 
very steep increase of N p-O T  during pregnancy one 
would expect a strong increase in release of OT during 
pregnancy. Surprisingly, circulating O T levels remained 
low during pregnancy up to day 253 of gestation. Further­
more, after pregnancy, N p-O T declined while circulating 
O T  increased. This again may be explained by an in­
creased CAP breakdown of O T during pregnancy and 
consequently an elevated M C R  (Thornton et al 1992). In 
addition, Amico & Hempel (1990) supplied evidence for 
altered post-translational processing of OT-prohormone 
during oestrogenic stimulation (pregnancy), leading to 
non-immunoreactive OT-glycine instead of OT. Possibly, 
our Higuchi OT antibody does not cross-react with 
OT-glycine and therefore immunoreactive OT levels 
remained low during pregnancy. This could also explain 
the undetectable OT urinary excretion in our study during
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pregnancy. Since O T and N p-O T did not change during 
salt restriction we considered this issue, interesting though 
it may be, to be beyond the scope of this study and we did 
not investigate this further. A total of 21 mothers were 
breastfeeding. Plasma values for both Np-OT (P= 0-06) 
and OT (P= 0*99) were not different between women 
who were breastfeeding and those who were not, although 
Np-OT values in breastfeeding mothers tended to be 
higher. Median (range) plasma N p-O T values in mothers 
who were breastfeeding compared with those who were
not were 1*3 ng/ml (0*7—5*5) vs 0*6 (0*55—0*95). Finally,
one must consider the possibility that increased Np-OT is 
of uterine origin as can be inferred from studies by Chibbar
et al (1993).
We could not demonstrate an effect of hypertension on 
any of the parameters measured. About 5-10% of the 
women enrolled in the study were expected to develop 
hypertension. In our study group, four women developed 
hypertension (8%), which is too low a number to enable 
any conclusion to be drawn. On the other hand, an earlier 
study did not support a role for AVP in pregnancy-induced 
hypertension (van der Post et al. 1993).
In conclusion, this study provides evidence for de­
creased renal AVP excretion during chronic severe sodium 
restriction in human pregnancy without a significant 
change in circulating AVP and O T levels or platelet- 
bound AVP, despite the known decrease in circulating 
volume. No evidence was found for non-osmotic AVP 
release during pregnancy or chronic dietary sodium 
restriction.
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